A Technology Transfer Training Programme is underway between the ICGEB Biotechnology Development Unit and the Developing Countries Vaccine Manufacturers Network (DCVMN International).
Ten participants from nine DCVMN member companies are attending the training. They will return to their organisations equipped to share knowledge with colleagues and amplify the impact of this training across their teams and countries, as they translate their learnings into action.
This exclusive Programme revolves around training a group of LMIC participants on Technology Transfer using a hybrid format of training delivery that includes a five-week online segment to cover the theoretical foundations of technology transfer, including:
🔸 Intellectual property and licensing (IP)
🔹 GMP and regulatory considerations
🔸 Different vaccine process platforms and their implications
🔹 A step-by-step roadmap for executing successful technology transfers
🔸 Common pitfalls and risk-mitigation strategies
Following successful completion of the online training, participants move to the onsite training at the ICGEB in Trieste, Italy, where they are offered an immersive hands-on experience over a week. “This allows participants to experience the concepts learned in a live GMP-like environment where they learn by doing”, states Dr. Natasa Skoko, Head of the BDU and responsible for the training.
This programme constitutes the 6th edition of the DCVMN Technology Transfer Training and the first such collaboration with ICGEB.
DCVMN is a voluntary public health-driven alliance of vaccine manufacturers from developing countries, firmly engaged in innovation, research, development, manufacturing, and supply of high-quality vaccines, striving to accelerate global vaccine equity and protect people against known and emerging infectious diseases globally.
ICGEB, with its Technology Transfer Office and its Biotechnology Development Unit, provides expertise, technical assistance, and training covering the topics of technology transfer for pharma and particularly for biomanufacturing activities, covering all aspects, both theoretical and practical, and including upstream, downstream, and quality aspects, according to GMP practices.
The Biotechnology Development Unit (BDU), located in Trieste, focuses on the development of technologies to produce biotherapeutic products and technology transfer. The objective of the BDU is to support capacity building and the availability of high-quality biotherapeutics by increasing the know-how and capabilities of the pharmaceutical industry in ICGEB Member States. This joint training is a great reflection of how this can be achieved.
